The Protective Effects of Osteocyte-Derived Extracellular Vesicles Against Alzheimer's Disease Diminished with Aging

Both Alzheimer's disease (AD) and osteoporosis (OP) are common age-associated degenerative diseases and are strongly correlated with clinical epidemiology. However, there is a lack of clear pathological relationship between the brain and bone in the current understanding. Here, it is found that young osteocyte, the most abundant cells in bone, secretes extracellular vesicles (OCYYoung-EVs) to ameliorate cognitive impairment and the pathogenesis of AD in APP/PS1 mice and model cells. These benefits of OCYYoung-EVs are diminished in aged osteocyte-derived EVs (OCYAged-EVs). Based on the self-constructed OCY-EVs tracer transgenic mouse models and the in vivo fluorescent imaging system, OCY-EVs have been observed to be transported to the brain under physiological and pathological conditions. In the hippocampal administration of A beta 40 induced young AD model mice, the intramedullary injection of Rab27a-shRNA adenovirus inhibits OCYYoung-EVs secretion from bone and aggravates cognitive impairment. Proteomic quantitative analysis reveals that OCYYoung-EVs, compared to OCYAged-EVs, enrich multiple protective factors of AD pathway. The study uncovers the role of OCY-EV as a regulator of brain health, suggesting a novel mechanism in bone-brain communication.

Automated summary

This study reveals that extracellular vesicles released by young osteocytes have beneficial effects on improving cognitive impairment and the pathogenesis of Alzheimer's disease, while those released by aged osteocytes do not have this effect. These vesicles can be transported to the brain under physiological and pathological conditions. Proteomic analysis shows that compared to aged vesicles, young vesicles contain multiple protective factors of Alzheimer's disease pathway.